MX2009011745A - Uso de moduladores del receptor de tromboxano para el tratamiento de trastornos cardiovasculares en poblaciones sensibles a aspirina y otras. - Google Patents

Uso de moduladores del receptor de tromboxano para el tratamiento de trastornos cardiovasculares en poblaciones sensibles a aspirina y otras.

Info

Publication number
MX2009011745A
MX2009011745A MX2009011745A MX2009011745A MX2009011745A MX 2009011745 A MX2009011745 A MX 2009011745A MX 2009011745 A MX2009011745 A MX 2009011745A MX 2009011745 A MX2009011745 A MX 2009011745A MX 2009011745 A MX2009011745 A MX 2009011745A
Authority
MX
Mexico
Prior art keywords
cardiovascular disorders
treatment
modulators
populations
inhibitor
Prior art date
Application number
MX2009011745A
Other languages
English (en)
Inventor
David R Phillips
Patrick Andre
Charles J Homcy
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of MX2009011745A publication Critical patent/MX2009011745A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención proporciona métodos y composiciones útiles en el tratamiento o prevención de trastornos cardiovasculares en individuos para quienes no es factible la terapia con un inhibidor de enzima COX-1, debido a sensibilidad, intolerancia, o resistencia al inhibidor. Adicionalmente, la invención proporciona métodos para tratar trastornos cardiovasculares en un individuo quien está recibiendo una dosis terapéuticamente efectiva de un modulador de TP y se instruye o aconseja evitar y/o no tomar aspirina u otro inhibidor de COX-1.
MX2009011745A 2007-05-03 2008-05-02 Uso de moduladores del receptor de tromboxano para el tratamiento de trastornos cardiovasculares en poblaciones sensibles a aspirina y otras. MX2009011745A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US91578507P 2007-05-03 2007-05-03
US91578407P 2007-05-03 2007-05-03
US94728907P 2007-06-29 2007-06-29
US94731607P 2007-06-29 2007-06-29
PCT/US2008/062565 WO2008137791A1 (en) 2007-05-03 2008-05-02 Use of tp modulators for the treatment of cardiovascular disorders in aspirin sensitive and other populations

Publications (1)

Publication Number Publication Date
MX2009011745A true MX2009011745A (es) 2010-02-12

Family

ID=39943967

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2009011744A MX2009011744A (es) 2007-05-03 2008-05-02 Formulaciones de dosis unitaria y metodos para tratar y prevenir trombosis con antagonistas del receptor de tromboxano.
MX2009011745A MX2009011745A (es) 2007-05-03 2008-05-02 Uso de moduladores del receptor de tromboxano para el tratamiento de trastornos cardiovasculares en poblaciones sensibles a aspirina y otras.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2009011744A MX2009011744A (es) 2007-05-03 2008-05-02 Formulaciones de dosis unitaria y metodos para tratar y prevenir trombosis con antagonistas del receptor de tromboxano.

Country Status (10)

Country Link
US (2) US20090012136A1 (es)
EP (2) EP2144999A4 (es)
JP (2) JP2010526104A (es)
KR (2) KR20100032854A (es)
CN (2) CN101686668A (es)
AU (2) AU2008247441A1 (es)
CA (2) CA2688317A1 (es)
IL (2) IL201885A0 (es)
MX (2) MX2009011744A (es)
WO (2) WO2008137791A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100168137A1 (en) * 2006-12-20 2010-07-01 Johan Raud Combination for use in the treatment of inflammatory disorders
WO2008087371A1 (en) * 2007-01-16 2008-07-24 Cardoz Ab New combination for use in the treatment of inflammatory disorders
US20130197044A1 (en) * 2010-07-14 2013-08-01 Leo Pavliv Methods of treating hepatorenal syndrome and hepatic encephalopathy with thromboxane-a2 receptor antagonists
CA2857953A1 (en) 2011-11-07 2013-05-16 Diakron Pharmaceuticals Inc. An extended release formulation of a direct thrombin inhibitor
JP6183459B2 (ja) * 2012-08-06 2017-08-23 Jnc株式会社 合成コラーゲンを用いる二重抗血小板薬／アスピリン応答および反応性試験
ES2848348T3 (es) 2014-05-16 2021-08-06 Cumberland Pharmaceuticals Inc Composiciones y métodos de tratamiento con ifetroban de la fibrosis cardíaca
CN114569608A (zh) * 2015-06-30 2022-06-03 坎伯兰医药品股份有限公司 Aerd/哮喘中的血栓烷受体拮抗剂
ES2955158T3 (es) 2016-05-11 2023-11-29 Cumberland Pharmaceuticals Inc Composiciones y métodos de tratamiento de la distrofia muscular con antagonistas del receptor de tromboxano-A2

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3895115A (en) * 1974-03-01 1975-07-15 Serono Ist Farm Method of inhibiting platelet aggregation
US5071866A (en) * 1989-07-31 1991-12-10 Bristol-Myers Squibb Company Arylpyrazole derivatives as anti-platelet agents
US5506248A (en) * 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
US5605917A (en) * 1994-12-22 1997-02-25 Bristol-Myers Squibb Company Method of treating dysmenorrhea employing an interphenylene 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analog
US6509348B1 (en) * 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
WO2004004776A1 (en) * 2002-07-09 2004-01-15 B.M.R.A. Corporation B.V. Phamaceutical combination of a thromboxane a2 receptor antagonist and a cox-2 inhibitor
WO2006066008A2 (en) * 2004-12-14 2006-06-22 Portola Pharmaceuticals, Inc. Device and methods for identifying and treating aspirin non-responsive patients
US7381536B2 (en) * 2005-03-01 2008-06-03 Gurbel Paul A Assessment of cardiac health and thrombotic risk in a patient

Also Published As

Publication number Publication date
CN101711279A (zh) 2010-05-19
AU2008247441A1 (en) 2008-11-13
US20090012136A1 (en) 2009-01-08
MX2009011744A (es) 2010-02-12
IL201885A0 (en) 2011-08-01
IL201886A0 (en) 2010-06-16
EP2146573A1 (en) 2010-01-27
AU2008247439A1 (en) 2008-11-13
JP2010526104A (ja) 2010-07-29
CN101686668A (zh) 2010-03-31
EP2146573A4 (en) 2012-11-21
CA2688319A1 (en) 2008-11-13
KR20100037029A (ko) 2010-04-08
CA2688317A1 (en) 2008-11-13
US20090012115A1 (en) 2009-01-08
WO2008137793A1 (en) 2008-11-13
KR20100032854A (ko) 2010-03-26
EP2144999A4 (en) 2010-06-16
JP2010527331A (ja) 2010-08-12
WO2008137791A1 (en) 2008-11-13
EP2144999A1 (en) 2010-01-20

Similar Documents

Publication Publication Date Title
MX2009011745A (es) Uso de moduladores del receptor de tromboxano para el tratamiento de trastornos cardiovasculares en poblaciones sensibles a aspirina y otras.
TN2009000381A1 (en) C5 antigens and uses thereof
EP4275752A3 (en) Treatment of addiction and impulse-control disorders using pde7 inhibitors
AU2008232453A8 (en) Methods and compositions for reduction of side effects of therapeutic treatments
WO2016077632A3 (en) Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications
MX2009002496A (es) Combinaciones que contienen un derivado de 4-acilaminopiridina.
MY145070A (en) Imidazolothiazole compounds for the treatment of disease
CA3010887A1 (en) Axl-specific antibody-drug conjugates for cancer treatment
MX2009012177A (es) Moduladores de gamma-secretasa.
NO20083202L (no) ANG2- og VEFG-inhibitorkombinasjoner
MX2010001506A (es) Moduladores de gamma secretasa.
MX2010005244A (es) Composiciones y métodos para la terapia y el diagnóstico de influenza.
ZA200807879B (en) Use of bifidobacterium longum for the prevention and treatment of inflammation
MX2010003117A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
MX2010006823A (es) Metodos para el tratamiento de la gota.
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
TW200728285A (en) Diacylindazole derivatives as inhibitors of lipases and phospholipases
WO2007103373A3 (en) Compositions and methods for the treatment of immunoinflammatory disorders
MX2009011949A (es) Inhibidores de proteina activadora de 5-lipoxigenasa (flap).
MX2011006150A (es) Compuestos inhibidores de cinasa.
WO2008036846A3 (en) Combination comprising an hmg-coa reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
EA201390506A1 (ru) Полипептиды, которые связывают компонент с5 комплемента человека
WO2021203103A3 (en) Ace2 receptor polymorphisms and varying susceptibility to sars-cov-2, methods for diagnosis and treatment
WO2009031606A1 (ja) 関節炎治療及び予防剤
MX2010003397A (es) Moduladores de la gamma secretasa.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal